VRTX - Vertex Pharmaceuticals, Inc.
IEX Last Trade
495.58
2.230 0.450%
Share volume: 1,809,551
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$493.35
2.23
0.45%
Fundamental analysis
46%
Profitability
67%
Dept financing
7%
Liquidity
62%
Performance
30%
Performance
5 Days
3.04%
1 Month
-1.34%
3 Months
11.93%
6 Months
16.14%
1 Year
41.38%
2 Year
76.25%
Key data
Stock price
$495.58
DAY RANGE
N/A - N/A
52 WEEK RANGE
$340.83 - $510.64
52 WEEK CHANGE
$0.41
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Reshma Kewalramani
Region: US
Website: https://www.vrtx.com/
Employees: 4,800
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.vrtx.com/
Employees: 4,800
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Recent news